Compare DNLI & PJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNLI | PJT |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.9B |
| IPO Year | 2017 | 2015 |
| Metric | DNLI | PJT |
|---|---|---|
| Price | $20.04 | $153.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $34.33 | ★ $174.25 |
| AVG Volume (30 Days) | ★ 1.2M | 302.7K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,713,671,000.00 |
| Revenue This Year | N/A | $11.12 |
| Revenue Next Year | $408.85 | $9.98 |
| P/E Ratio | ★ N/A | $23.03 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $12.58 | $127.73 |
| 52 Week High | $23.77 | $195.62 |
| Indicator | DNLI | PJT |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 52.92 |
| Support Level | $18.86 | $127.73 |
| Resistance Level | $20.71 | $186.13 |
| Average True Range (ATR) | 0.85 | 5.15 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 35.74 | 35.81 |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.